Biotech Values

[DewDiligence]

MRK +4% on GS upgrade:

https://www.barrons.com/articles/buy-merck-stock-for-its-unappreciated-pipeline-says-goldman-51596466053

Merck’s cancer drug Keytruda is such a success that investors now fret about its patent expiration toward the decade’s end. But plenty more of value lies behind the company’s stock, says Goldman Sachs analyst Terrence Flynn. The drug giant is brewing up new vaccines, as well as treatments for cancer and HIV, Flynn says, and has plenty of cash to acquire promising products. So in a Monday morning report, Goldman upgraded Merck stock to Buy from Hold.

LOL re the banality of the above. No mention of MRK’s Animal Health division, which has been putting up some great numbers.

p.s. MRK’s separation into two companies is still on track for 1H21 (#msg-153661332).